Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 350

1.

Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for in Vivo Multiplexing Studies.

Si P, Shevidi S, Yuan E, Yuan K, Lautman Z, Jeffrey SS, Sledge GW, de la Zerda A.

Nano Lett. 2019 Oct 10. doi: 10.1021/acs.nanolett.9b03344. [Epub ahead of print]

PMID:
31585502
2.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr.

JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794. [Epub ahead of print]

PMID:
31566680
3.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A.

JAMA Oncol. 2019 Sep 29. doi: 10.1001/jamaoncol.2019.4782. [Epub ahead of print]

PMID:
31563959
4.

Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.

Ramani VC, Lemaire CA, Triboulet M, Casey KM, Heirich K, Renier C, Vilches-Moure JG, Gupta R, Razmara AM, Zhang H, Sledge GW, Sollier E, Jeffrey SS.

Breast Cancer Res. 2019 Aug 28;21(1):98. doi: 10.1186/s13058-019-1182-4.

5.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
6.

Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods.

Dutta R, Liba O, SoRelle ED, Winetraub Y, Ramani VC, Jeffrey SS, Sledge GW, de la Zerda A.

Nano Lett. 2019 Apr 10;19(4):2334-2342. doi: 10.1021/acs.nanolett.8b05005. Epub 2019 Mar 29.

PMID:
30895796
7.

Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer.

Sledge GW.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):4769-4771. doi: 10.1073/pnas.1900368116. Epub 2019 Feb 22. No abstract available.

8.

Patients and Physicians in the Era of Modern Cancer Care.

Sledge GW.

JAMA. 2019 Mar 5;321(9):829-830. doi: 10.1001/jama.2018.17334. No abstract available.

PMID:
30768154
9.

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW.

JNCI Cancer Spectr. 2018 Nov;2(4):pky062. doi: 10.1093/jncics/pky062. Epub 2018 Dec 24.

10.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.

Di Leo A, O'Shaughnessy J, Sledge GW Jr, Martin M, Lin Y, Frenzel M, Hardebeck MC, Smith IC, Llombart-Cussac A, Goetz MP, Johnston S.

NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.

11.

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sparano J, O'Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, Sledge GW, Miller KD.

JAMA Oncol. 2018 Dec 1;4(12):1700-1706. doi: 10.1001/jamaoncol.2018.2574.

12.

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr.

J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24.

13.

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available.

14.

Local Control of Distant Disease: Yes, but Where to Next?

Sledge GW Jr.

J Oncol Pract. 2018 Jun;14(6):357-358. doi: 10.1200/JOP.18.00247. No abstract available.

PMID:
29894663
15.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

16.

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.

Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP.

Breast Cancer Res Treat. 2018 Aug;171(1):21-31. doi: 10.1007/s10549-018-4807-x. Epub 2018 May 7. Review.

PMID:
29736741
17.

Molecular Characterization and Mortality From Breast Cancer in Men.

Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S.

J Clin Oncol. 2018 May 10;36(14):1396-1404. doi: 10.1200/JCO.2017.76.8861. Epub 2018 Mar 27.

18.

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.

Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.

Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.

19.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

20.

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D.

Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.

21.

Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.

Schneider BP, Shen F, Jiang G, O'Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA, Sledge GW Jr, Miller KD.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00059. Epub 2017 Aug 21.

22.

Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.

Tanaka H, Phipps EA, Wei T, Wu X, Goswami C, Liu Y, Sledge GW Jr, Mina L, Herbert BS.

Mol Carcinog. 2018 Apr;57(4):567-575. doi: 10.1002/mc.22773. Epub 2018 Jan 5.

23.

Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?

Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW, Schneider BP.

Breast Cancer Res Treat. 2017 Oct;165(3):545-553. doi: 10.1007/s10549-017-4338-x. Epub 2017 Jun 23.

24.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW.

Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16.

25.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A.

J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.

PMID:
28580882
26.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM.

Cancer. 2017 Jul 1;123(13):2444-2451. doi: 10.1002/cncr.30682. Epub 2017 May 2.

27.

Survival benefit needed to undergo chemotherapy: Patient and physician preferences.

Vaz-Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider B, Partridge AH.

Cancer. 2017 Aug 1;123(15):2821-2828. doi: 10.1002/cncr.30671. Epub 2017 Mar 21.

28.

Put Some PEPI in Your Step: Ki67's Long Road to Respectability.

Sledge GW Jr.

J Clin Oncol. 2017 Apr 1;35(10):1031-1032. doi: 10.1200/JCO.2016.71.2182. Epub 2017 Feb 21. No abstract available. Erratum in: J Clin Oncol. 2017 Jul 1;35(19):2220.

PMID:
28221864
29.

Reply to L.B. Marks et al.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2017 Apr 10;35(11):1258-1259. doi: 10.1200/JCO.2016.71.3966. Epub 2017 Jan 9. No abstract available.

PMID:
28068171
30.

Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.

Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr.

Clin Cancer Res. 2017 Jan 1;23(1):43-51. doi: 10.1158/1078-0432.CCR-16-0908. Epub 2016 Dec 19.

31.

Synergistic drug combinations from electronic health records and gene expression.

Low YS, Daugherty AC, Schroeder EA, Chen W, Seto T, Weber S, Lim M, Hastie T, Mathur M, Desai M, Farrington C, Radin AA, Sirota M, Kenkare P, Thompson CA, Yu PP, Gomez SL, Sledge GW Jr, Kurian AW, Shah NH.

J Am Med Inform Assoc. 2017 May 1;24(3):565-576. doi: 10.1093/jamia/ocw161.

32.

Research needs in breast cancer.

Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA.

Ann Oncol. 2017 Feb 1;28(2):208-217. doi: 10.1093/annonc/mdw571.

PMID:
27831505
33.

Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.

Schneider BP, Lai D, Shen F, Jiang G, Radovich M, Li L, Gardner L, Miller KD, O'Neill A, Sparano JA, Xue G, Foroud T, Sledge GW Jr.

Oncotarget. 2016 Dec 13;7(50):82244-82253. doi: 10.18632/oncotarget.12545.

34.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e219-e234. doi: 10.1016/j.prro.2016.08.009. Epub 2016 Sep 19. Review.

PMID:
27659727
35.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2016 Dec 20;34(36):4431-4442. doi: 10.1200/JCO.2016.69.1188. Epub 2016 Sep 30. Review.

PMID:
27646947
36.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Ann Surg Oncol. 2017 Jan;24(1):38-51. doi: 10.1245/s10434-016-5558-8. Epub 2016 Sep 19.

37.

Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.

Xu D, Jalal SI, Sledge GW, Meroueh SO.

Mol Biosyst. 2016 Oct 20;12(10):3067-87. doi: 10.1039/c6mb00231e. Epub 2016 Jul 25.

38.

Aberrant nocturnal cortisol and disease progression in women with breast cancer.

Zeitzer JM, Nouriani B, Rissling MB, Sledge GW, Kaplan KA, Aasly L, Palesh O, Jo B, Neri E, Dhabhar FS, Spiegel D.

Breast Cancer Res Treat. 2016 Jul;158(1):43-50. doi: 10.1007/s10549-016-3864-2. Epub 2016 Jun 17.

39.

Collective Wisdom: Lobular Carcinoma of the Breast.

Sledge GW, Chagpar A, Perou C.

Am Soc Clin Oncol Educ Book. 2016;35:18-21. doi: 10.14694/EDBK_100002. No abstract available.

40.

Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.

Afghahi A, Mathur M, Thompson CA, Mitani A, Rigdon J, Desai M, Yu PP, de Bruin MA, Seto T, Olson C, Kenkare P, Gomez SL, Das AK, Luft HS, Sledge GW Jr, Sing AP, Kurian AW.

J Oncol Pract. 2016 Jun;12(6):e697-709. doi: 10.1200/JOP.2015.009803. Epub 2016 May 24.

41.

Integrated digital error suppression for improved detection of circulating tumor DNA.

Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW, Shrager JB, Loo BW Jr, Neal JW, Wakelee HA, Diehn M, Alizadeh AA.

Nat Biotechnol. 2016 May;34(5):547-555. doi: 10.1038/nbt.3520. Epub 2016 Mar 28.

42.

Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors.

Adams RN, Mosher CE, Cohee AA, Stump TE, Monahan PO, Sledge GW Jr, Cella D, Champion VL.

Psychooncology. 2017 Jul;26(7):982-990. doi: 10.1002/pon.4119. Epub 2016 Mar 10.

43.

Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology.

Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, Garon EB, Goldman J, Rao J, Sledge GW, Pegram MD, Sheth S, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D.

Oncotarget. 2016 Mar 15;7(11):12748-60. doi: 10.18632/oncotarget.7220.

44.

Curing Metastatic Breast Cancer.

Sledge GW Jr.

J Oncol Pract. 2016 Jan;12(1):6-10. doi: 10.1200/JOP.2015.008953. Review.

PMID:
26759458
45.

Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure.

Sledge GW Jr.

J Clin Oncol. 2016 Apr 1;34(10):1021-3. doi: 10.1200/JCO.2015.64.7511. Epub 2015 Dec 23. No abstract available.

PMID:
26700125
46.

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).

Schneider BP, O'Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, Zander PJ, Davidson NE.

Br J Cancer. 2015 Dec 22;113(12):1651-7. doi: 10.1038/bjc.2015.405. Epub 2015 Dec 1.

47.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

48.

Targeted Therapy for Cancer in the Genomic Era.

Afghahi A, Sledge GW Jr.

Cancer J. 2015 Jul-Aug;21(4):294-8. doi: 10.1097/PPO.0000000000000135. Review.

PMID:
26222081
49.

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.

Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr.

Clin Cancer Res. 2015 Nov 15;21(22):5082-5091. doi: 10.1158/1078-0432.CCR-15-0586. Epub 2015 Jul 2.

50.

Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.

Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT Jr, Northfelt DW, Sledge GW Jr.

JAMA Oncol. 2015 Jun;1(3):369-74.

Supplemental Content

Loading ...
Support Center